Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Diabetes Costs and Affordability in the United States
Jun 29, 2020
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

ABOUT THE REPORT

Even in the current healthcare climate, which is feeling the impact of the social and economic disruptions related to COVID-19, healthcare and medicine costs remain a key concern for patients, payers, and policymakers. Diabetes is a high-profile therapy area that is often considered a driver of financial challenges for both payers and patients. It has a large and growing patient population, ranks among the top three therapy classes in terms of both utilization and drug spend for both commercial payers and Medicare, and contributes significantly to CMS costs due to high volumes dispensed. However, several key misunderstandings persist around the prices of these critical medicines. As policymakers consider significant changes to U.S. drug pricing, including rules potentially impacting diabetes pricing, this report provides analyses of pricing, and context to inform those decisions.

REPORT SUMMARY

Diabetes costs have been a significant focus for stakeholders. The report provides detailed analyses around diabetes drug pricing, including list price, net manufacturer price, and out-of-pocket costs for patients as a function of various insurance programs. Diabetes prices have risen significantly in the past five years on a list-price basis though manufacturer net revenues have been declining and for patient out-of-pocket costs, reductions have not been uniformly observed though they have been flat or have risen only slightly overall. The report also looks at prescription abandonment related to out-of-pocket costs, and how these costs can interrupt a patient’s ability to pay. The report examines the impact of insurance coverage and finds that commercially-insured patients have higher initial cost exposure than Medicare patients, but can use coupons to offset costs and a significant proportion are doing so, such that their final out-of-pocket costs are similar to that of Medicare patients. Finally, the report details current U.S. policies and other shifts in the diabetes landscape that will impact diabetes spending over the next few years.

Key Findings

PRICING

Invoice prices for diabetes medicines have been growing above inflation while net prices have been declining-to-flat for five years

  • The use of price-protection contracts and the presence of statutory rebates in Medicaid are among the most impactful drivers of lower net prices.
  • As net prices have declined, patient out-of-pocket costs have been flat to rising slightly.




PATIENT OUT-OF-POCKET COST

Initial copays for diabetes medicines are higher for commercial patients than Medicare patients, though their final out-of-pocket costs are similar

  • For most commercially-insured patients, fixed copays still apply in traditional insurance plans, while a rising proportion have high-deductible health plans (HDHP).
  • Newer generation drugs have been less preferred within certain commercial plans than historically, leading to higher copays, though much of this higher cost exposure has been offset through coupons.



ABANDONMENT

Diabetes patients facing higher costs have higher abandonment rates for prescriptions, however, the percentage of claims greater than $91 dollars is below 10% of total claims

  • Abandonment is a term reflecting the preparation of a prescription for an individual patient which is not taken home, and for diabetes patients, abandonment is highest when costs are above $91.
  • The majority of diabetes prescriptions are low-cost — with less than $30 patient out-of-pocket cost — and only 4% of patients abandon those prescriptions at the pharmacy.




POLICY IMPACT

Recent policies and environmental factors, such as updated tax rules and availability of novel biosimilars, have the potential to lower patient costs for diabetes

  • The IRS extended the group of therapies that are considered preventive in high-deductible plans with health savings accounts (HDHP/HSA). Diabetics could benefit from savings for several of their drugs or medical supplies including hypertension, heart disease, cholesterol among others.
  • The new CMS Senior Savings Model for diabetes would enable some plans to offer lower patient costs for diabetes and as with all Part D plan choices.
  • Non-original versions of insulin glargine and lispro, while not approved through the biosimilar pathway, continue to contribute to lower costs for some patients and will likely see wider uptake.
Contact Us